Legend Biotech Corp (LEGN) Q3 2026 Earnings Call Highlights: CARVYKTI Sales Jump 36%
Legend Biotech (LEGN) reported a 36% increase in CARVYKTI sales for Q3 2026, but U.S. sales were flat. Management noted slower-than-expected U.S. growth and launch delays in ex-U.S. markets. R&D expenses declined 16% year-over-year, but future spending may increase. CARVYKTI's U.S. sales mix shifted toward earlier lines, and the company expects double-digit growth in 2027. LB2501 dose level 3 showed lower efficacy than dose level 2, and there were no updates on LB2505.
How this was made

The 30-second read
Why it matters
The mixed data and flat sales suggest near‑term downside risk, but long‑term growth guidance and expanding European footprint provide upside catalysts.
Market read
The earnings call provides fresh guidance and trial data that can move LEGN and influence the broader BCMA CAR‑T sector.
What to watch
Potential for improved margins from manufacturing efficiencies and expanding ex‑U.S. market share may offset near‑term sales flatness.
Background
Legend Biotech discussed Q3 2026 performance of its CAR‑T product CARVYKTI, trial updates for LB2501, and outlook for upcoming CAR‑T programs.
Ticker impact
Q3 2026 earnings call disclosed flat U.S. CARVYKTI sales, guidance for double‑digit growth in 2027, and mixed LB2501 dose‑response data.
likely pressure as investors price in slower U.S. growth and trial uncertainty
First disclosure of sales flattening and new dose‑response data; guidance is modest and market may react negatively until data improves.
Market effects
Highlights competitive pressure from bispecifics like TECVAYLI and may prompt re‑rating of BCMA CAR‑T sector peers.
European launch delays could affect regional biotech exposure.
Trial data and guidance may influence broader immunotherapy investment sentiment.
Counterpoint
If the 2027 double‑digit growth materializes, the stock could rally on upside potential despite short‑term setbacks.
Key entities
- companyLegend Biotech Corp
US‑listed biotech developing BCMA CAR‑T therapies.
- partnerJohnson & Johnson
Collaboration partner for LB2505 program.


